Navigation Links
Bioniche Pharma and Synerx Launch Isosulfan Blue Injection 1%
Date:7/28/2010

LAKE FOREST, Ill., July 28 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.

(Photo:  http://photos.prnewswire.com/prnh/20100728/CG42156)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100728/CG42156)

(Logo:  http://photos.prnewswire.com/prnh/20080702/AQW070LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"Launching the first and only generic for Isosulfan Blue Injection 1% in the US reaffirms our commitment to introducing generic niche products, which allows hospitals and pharmacies an option in the buying process," said George Zorich, President, US Operations for Bioniche Pharma.

Isosulfan Blue Injection 1% will be supplied in a carton containing six 5mL (10 mg/mL)

single use vials.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anaesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma and prescribing information for its products can be found at www.bionichepharma.com.

About Synerx Pharma:

Synerx Pharma, LLC is a privately held corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has eight FDA approved products, of which five were First Time Generic Approvals, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at www.synerxpharma.com.

Lymphazurin™ is a trademark of Tyco Healthcare Group LP


'/>"/>
SOURCE Bioniche Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
2. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
3. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
4. Bioniche Pharma Launches Ibutilide Fumarate Injection
5. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
6. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
9. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market: Analysis By Procedure, Replacement Procedure By Technique, Repair Procedure By ... ... Valve Devices Market is forecasted to grow at a CAGR of ... devices is driven by rising aging population, growth in population with ...
(Date:3/23/2017)... March 23, 2017 ... created through extensive primary research (inputs from industry ... aims to present the analysis of global heart ... (Replacement and Repair); Replacement Procedure By Technique (Mechanical, ... Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral Valve ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... Vighter established its NAEMT Authorized Training Center ... Trauma Life Support (PHTLS) course scholarships to four medics assigned to the Minnesota ... cooperation with the American College of Surgeons to promote critical thinking in addressing ...
(Date:3/24/2017)... , ... March 24, 2017 , ... According to a ... is invalid because it does not obey the rules Congress has directed the CBO ... jobs, which the GOP reform would restore. Yet, it estimates a reduction in employer-based ...
(Date:3/24/2017)... ... 24, 2017 , ... In just two days, Aqua Design ... garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the original ... (and counting) already backing the campaign. , “We are very grateful for ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Viewers who ... variety of critical historical facts, cultural practices, goods, services, and societal issues tend to ... will look into the popular practice of utilizing running events for causes around the ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
Breaking Medicine News(10 mins):